DK0525149T3
(da)
*
|
1991-01-10 |
1997-12-01 |
Amylin Pharmaceuticals Inc |
Amylinaktivitetsassays
|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
US5814600A
(en)
*
|
1991-05-24 |
1998-09-29 |
Amylin Pharmaceuticals Inc. |
Method and composition for treatment of insulin requiring mammals
|
AU669110B2
(en)
*
|
1991-05-24 |
1996-05-30 |
Amylin Pharmaceuticals, Inc. |
Amylin and possibly insulin containing composition for the treatment of anorexia and related states
|
ATE205854T1
(de)
*
|
1991-11-19 |
2001-10-15 |
Amylin Pharmaceuticals Inc |
Peptide als amylin-agonisten und ihre verwendung
|
JP3821839B2
(ja)
*
|
1993-09-07 |
2006-09-13 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
胃腸の運動性を調節する方法
|
GB9409496D0
(en)
|
1994-05-12 |
1994-06-29 |
London Health Ass |
Method for improving glycaemic control in diabetes
|
US5763200A
(en)
*
|
1995-05-12 |
1998-06-09 |
Biomeasure, Incorporated |
Inhibition of amylin release
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
US5677279A
(en)
*
|
1996-12-16 |
1997-10-14 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating pain with amylin or agonists thereof
|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7101853B2
(en)
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
US7910548B2
(en)
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
WO2000078805A1
(en)
*
|
1999-06-18 |
2000-12-28 |
Protemix Corporation Limited |
Peptide having preptin functionality
|
WO2001056594A1
(en)
|
2000-02-04 |
2001-08-09 |
Unigene Laboratories, Inc. |
Nasal calcitonin formulations
|
AU2002230509A1
(en)
*
|
2000-11-28 |
2002-06-11 |
Martin G. Baum |
Devices and methods for treating low blood sugar levels
|
US20030208113A1
(en)
*
|
2001-07-18 |
2003-11-06 |
Mault James R |
Closed loop glycemic index system
|
US20040038861A1
(en)
*
|
2001-11-26 |
2004-02-26 |
Cooper Garth J. S. |
Methods and compositions for normalizing lipid levels in mammalian tissues
|
US20040009976A1
(en)
*
|
2002-04-30 |
2004-01-15 |
Kumiko Takeuchi |
Hypoglycemic imidazoline compounds
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US8168233B2
(en)
*
|
2002-10-18 |
2012-05-01 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
WO2004060387A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
KR101196036B1
(ko)
*
|
2003-07-01 |
2012-10-31 |
에센티스 에이비 |
영양실조 또는 높은 혈장 글루코스 상태를 치료하기 위한알파-케토글루타르산의 용도
|
US7591801B2
(en)
|
2004-02-26 |
2009-09-22 |
Dexcom, Inc. |
Integrated delivery device for continuous glucose sensor
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
AU2006213607A1
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Llc |
GIP analog and hybrid polypeptides with selectable properties
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
JP5114381B2
(ja)
*
|
2005-03-31 |
2013-01-09 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
精神疾患および障害治療用アミリンおよびアミリンアゴニスト
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
JP2009538824A
(ja)
|
2006-03-31 |
2009-11-12 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
精神疾患及び障害治療用アミリン及びアミリンアゴニスト
|
US20090181890A1
(en)
*
|
2006-03-31 |
2009-07-16 |
Amylin Pharmaceuticals , Inc. |
Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
|
US8536120B2
(en)
*
|
2006-04-28 |
2013-09-17 |
The Administrators Of The Tulane Educational Fund |
Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
US20080076721A1
(en)
*
|
2006-09-25 |
2008-03-27 |
Sal Abraham |
Use of branched chain fatty acid amino acid salts and compositions thereof
|
EP2036539A1
(en)
*
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
EP2227132B1
(en)
|
2007-10-09 |
2023-03-08 |
DexCom, Inc. |
Integrated insulin delivery system with continuous glucose sensor
|
EP4250312A3
(en)
|
2007-10-25 |
2023-11-01 |
DexCom, Inc. |
Systems and methods for processing sensor data
|
CN102348715B
(zh)
|
2009-02-03 |
2017-12-08 |
阿穆尼克斯运营公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
US9724381B2
(en)
|
2009-05-12 |
2017-08-08 |
The Administrators Of The Tulane Educational Fund |
Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
|
NZ596778A
(en)
|
2009-06-08 |
2013-11-29 |
Amunix Operating Inc |
Glucose-regulating polypeptides and methods of making and using same
|
CA2979950A1
(en)
|
2015-03-18 |
2016-09-22 |
Zealand Pharma A/S |
Amylin analogues
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
EP3562500B1
(fr)
|
2016-12-27 |
2023-07-19 |
Adocia |
Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
ES2969277T3
(es)
|
2017-07-27 |
2024-05-17 |
Adocia |
Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
US20190275108A1
(en)
|
2017-12-07 |
2019-09-12 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
|
CN111565710A
(zh)
|
2017-12-07 |
2020-08-21 |
阿道恰公司 |
包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
|
FR3083085B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
BR112020011486A2
(pt)
|
2017-12-07 |
2020-11-17 |
Adocia |
Solução injetável de ph 7 compreendendo pelo menos uma insulina basal comum pi de 5,8 a 8,5 e um copoliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
|
SG11202005319PA
(en)
|
2017-12-07 |
2020-07-29 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
|
FR3083086A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
CA3084688A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
FR3084586B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
|
EP4058466A1
(en)
|
2019-11-13 |
2022-09-21 |
Amunix Pharmaceuticals, Inc. |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|